Literature DB >> 15695780

Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease.

Daniel Weintraub1, Andrew B Newberg, Mark S Cary, Andrew D Siderowf, Paul J Moberg, Galit Kleiner-Fisman, John E Duda, Matthew B Stern, David Mozley, Ira R Katz.   

Abstract

UNLABELLED: We studied the correlation of striatal dopamine transporter (DAT) imaging with anxiety and depression symptoms in Parkinson's disease (PD).
METHODS: Patients with idiopathic PD (n = 76) and age-matched healthy volunteers (n = 46) underwent SPECT brain scans with (99m)Tc-TRODAT-1, a radiolabeled tropane that selectively binds to the DAT. TRODAT-1 distribution volume ratios, a reflection of DAT availability, were calculated from the SPECT scan data for 6 regions of interest (ROIs) in the caudate and putamen. The association between neuropsychiatric symptoms (anxiety, depression, and fatigue) and DAT availability was explored for both subject groups, and the impact of disease severity on this association was examined in the PD group.
RESULTS: PD patients showed lower DAT availability than did healthy volunteers in all examined regions (for all ROIs, P < 0.001). In PD patients, higher individual affective measures (for anxiety, r = -0.30 and P = 0.01; and for depression, r = -0.24 and P = 0.05) and total affect scores (r = -0.31; P = 0.01) were associated with diminished left anterior putamen DAT availability. The association between total affect scores and DAT availability was present only in the subset of patients with less severe PD (r = -0.35; P = 0.04), but subjects with the highest DAT availability did not show high total affect scores. No association between neuropsychiatric measures and DAT availability was found in the controls.
CONCLUSION: These preliminary findings suggest that decreased DAT availability may be necessary for but not invariably associated with the development of affective symptoms in PD. This suggestion is consistent with previous research showing a link between depression and basal ganglia impairment, particularly involving the left hemisphere, and extends this finding to include anxiety.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695780

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  60 in total

Review 1.  Stress, depression and Parkinson's disease.

Authors:  Ann M Hemmerle; James P Herman; Kim B Seroogy
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

2.  Predictors of anxiety in early-stage Parkinson's disease - Results from the first two years of a prospective cohort study.

Authors:  Sonja Rutten; Peter M van der Ven; Daniel Weintraub; Gregory M Pontone; Albert F G Leentjens; Henk W Berendse; Ysbrand D van der Werf; Odile A van den Heuvel
Journal:  Parkinsonism Relat Disord       Date:  2017-07-05       Impact factor: 4.891

Review 3.  Parkinson's disease: the quintessential neuropsychiatric disorder.

Authors:  Daniel Weintraub; David J Burn
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

4.  Molecular dynamics of conformation-specific dopamine transporter-inhibitor complexes.

Authors:  Bernandie Jean; Christopher K Surratt; Jeffry D Madura
Journal:  J Mol Graph Model       Date:  2017-07-11       Impact factor: 2.518

5.  Depression severity and concentration difficulties are independently associated with HRQOL in patients with unipolar depressive disorders.

Authors:  A Fattori; L Neri; A Bellomo; M Vaggi; C Mencacci
Journal:  Qual Life Res       Date:  2017-05-13       Impact factor: 4.147

6.  Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.

Authors:  Bernard Ravina; Kenneth Marek; Shirley Eberly; David Oakes; Roger Kurlan; Alberto Ascherio; Flint Beal; James Beck; Emily Flagg; Wendy R Galpern; Jennifer Harman; Anthony E Lang; Michael Schwarzschild; Caroline Tanner; Ira Shoulson
Journal:  Mov Disord       Date:  2012-09-13       Impact factor: 10.338

7.  Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study.

Authors:  Daniela Di Giuda; Giovanni Camardese; Anna Rita Bentivoglio; Fabrizio Cocciolillo; Arianna Guidubaldi; Lorella Pucci; Isabella Bruno; Luigi Janiri; Alessandro Giordano; Alfonso Fasano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-14       Impact factor: 9.236

Review 8.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

9.  Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT study: reply to comment by Erro et al.

Authors:  Daniela Di Giuda; Giovanni Camardese; Fabrizio Cocciolillo; Alfonso Fasano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-07       Impact factor: 9.236

10.  Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys.

Authors:  Pierre-Olivier Fernagut; Qin Li; Sandra Dovero; Piu Chan; Tao Wu; Paula Ravenscroft; Michael Hill; Zhenwen Chen; Erwan Bezard
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.